AU2002230889A1 - Target enzymes - Google Patents

Target enzymes

Info

Publication number
AU2002230889A1
AU2002230889A1 AU2002230889A AU3088902A AU2002230889A1 AU 2002230889 A1 AU2002230889 A1 AU 2002230889A1 AU 2002230889 A AU2002230889 A AU 2002230889A AU 3088902 A AU3088902 A AU 3088902A AU 2002230889 A1 AU2002230889 A1 AU 2002230889A1
Authority
AU
Australia
Prior art keywords
target enzymes
enzymes
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002230889A
Inventor
Yiyou Chen
Anthony G. Day
David A. Estell
Christopher J. Murray
Scott D. Power
Volker Schellenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor International Inc filed Critical Genencor International Inc
Publication of AU2002230889A1 publication Critical patent/AU2002230889A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002230889A 2000-12-14 2001-12-14 Target enzymes Abandoned AU2002230889A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60/000,000 2000-09-15
US25577400P 2000-12-14 2000-12-14
US60/255,774 2000-12-14
US27960901P 2001-03-28 2001-03-28
US60/279,609 2001-03-28
PCT/US2001/048528 WO2002048372A2 (en) 2000-12-14 2001-12-14 Target enzymes

Publications (1)

Publication Number Publication Date
AU2002230889A1 true AU2002230889A1 (en) 2002-06-24

Family

ID=26944947

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002230890A Abandoned AU2002230890A1 (en) 2000-12-14 2001-12-14 Targeted enzyme prodrug therapy
AU2002230889A Abandoned AU2002230889A1 (en) 2000-12-14 2001-12-14 Target enzymes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002230890A Abandoned AU2002230890A1 (en) 2000-12-14 2001-12-14 Targeted enzyme prodrug therapy

Country Status (2)

Country Link
AU (2) AU2002230890A1 (en)
WO (2) WO2002047717A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457458T1 (en) * 2003-12-18 2010-02-15 Genencor Int BETA-LACTAMASE CD4+ T CELL EPITOPES
JP4699450B2 (en) 2004-04-15 2011-06-08 ジェネンコー・インターナショナル・インク ADEP construction for CAB molecules and CEA
ITBG20120050A1 (en) * 2012-10-29 2013-01-28 Michele Mutti FUSION PROTEIN WITH PROTEASIC ACTIVITY AND SPECIFICITY OF ANTIBODIES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098524A1 (en) * 2000-04-14 2002-07-25 Murray Christopher J. Methods for selective targeting

Also Published As

Publication number Publication date
WO2002047717A3 (en) 2003-03-13
WO2002048372A3 (en) 2003-05-30
WO2002048372A2 (en) 2002-06-20
AU2002230890A1 (en) 2002-06-24
WO2002047717A9 (en) 2003-05-30
WO2002047717A2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2001267333A1 (en) Lipolytic enzyme
AU2002231352A1 (en) Sputtering target
AU2001279134A1 (en) Nucleotide incorporating enzymes
AU2002357860A1 (en) Enzymes
AUPQ598700A0 (en) Weapon
AU1878601A (en) Enzyme
AU2000267458A1 (en) Hypercomputer
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AUPQ749900A0 (en) Projectiles
AU2001288121A1 (en) Enzyme electrode
AU2576100A (en) Novel enzyme
AU2001275184A1 (en) Sputtering target
AU2002228716A1 (en) Sputtering target assemblies
AU2002347778A1 (en) Enzymes
AU2001295777A1 (en) Target
AU2001242625A1 (en) Gene sequence
AU2001269888A1 (en) Protein phosphatases
AU2001264247A1 (en) GASC1 gene
AU2001283012A1 (en) Protein phosphatases
AU2001246864A1 (en) Hypotensors
AU2001284047A1 (en) Butinol I esterase
AU2001247444A1 (en) Erbeta-mediated gene expression
AU2001292870A1 (en) Protein phosphatases
AU2001285743A1 (en) Adipose-related gene